StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE - Free Report) to a sell rating in a research report report published on Monday morning.
Pulse Biosciences Price Performance
PLSE traded up $0.16 on Monday, reaching $14.69. The company had a trading volume of 136,948 shares, compared to its average volume of 197,240. Pulse Biosciences has a 1 year low of $6.60 and a 1 year high of $25.00. The stock has a 50-day moving average price of $18.61 and a 200-day moving average price of $18.10.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pulse Biosciences by 14.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company's stock worth $667,000 after acquiring an additional 4,773 shares during the last quarter. Panoramic Capital LLC acquired a new stake in Pulse Biosciences during the 4th quarter worth $846,000. Deutsche Bank AG grew its position in Pulse Biosciences by 65.1% during the 4th quarter. Deutsche Bank AG now owns 16,795 shares of the company's stock worth $292,000 after purchasing an additional 6,625 shares during the last quarter. Bank of America Corp DE increased its stake in Pulse Biosciences by 0.4% in the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after purchasing an additional 2,884 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after buying an additional 838 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Recommended Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
